This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
TP63 · Western blot design guide
TP63 Western Blot Planning Guide
Plan a TP63 Western blot around the catalog-observed 76.8 kDa band, image-backed PA2056 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
TP63 Western Blot Experimental Design Guide
Expected bands, documented protocol parameters, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 76.8 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 12-15% | |
| Positive control | Esophagus | |
| Negative control | Adrenal gland |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 76.8 kDa |
| ⓘ | Localization | Nucleus |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Rat / Mouse / Human |
Section 1
Real Curated TP63 Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Breast |
| Gel % | 12-15% |
| Load | 20-30 µg total protein per lane |
| Transfer | Semi-dry, standard transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | PA2056 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected TP63 Western Blot Band Size?
Use the product-observed 76.8 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 76.8 kDa | Matches the authoritative product WB observation. |
| 76.8 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected TP63 appearancePlan around 76.8 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 76.8 kDa; use this as the primary experimental expectation. |
| Calculated mass | 76.8 kDa from UniProt Q9H3D4; retain as context. |
| Gel selection | 12-15%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with PA2056. |
| Situation | Likely cause | Next action |
|---|---|---|
| 76.8 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing TP63 band
PA2056 · TP63
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for TP63 Western blot
🧪Use Esophagus as the first positive-control candidate and Adrenal gland as the HPA Not detected negative candidate.
Positive control: Esophagus (High)
Negative control: Adrenal gland (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for TP63
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Esophagus | Reported tissue cells | High | Protein (HPA) | HPA → |
| Breast | Reported tissue cells | High | Protein (HPA) | HPA → |
| Cervix | Reported tissue cells | High | Protein (HPA) | HPA → |
| Bronchus | Reported tissue cells | High | Protein (HPA) | HPA → |
Section 3
Advanced TP63 Western Blot Tips
Deeper troubleshooting and optimisation questions for TP63, answered from its protein features.
Which band should guide the blot?
Use 76.8 kDa, the observation attached to the authoritative PA2056 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 76.8 kDa expectation.
Which positive control should I start with?
Start with Esophagus, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Adrenal gland as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 12-15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for TP63 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should PA2056 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents
TP63 Western Blot Reagents
Rat/Mouse/Human-reactive TP63 Western blot reagents with authoritative product imagery.
Real WB data
Anti-p63/TP63 Antibody Picoband®
Cat # PA2056
Real WB data
Anti-p63/TP63 Antibody Picoband®
Cat # PB9152
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt Q9H3D4
- Human Protein Atlas — TP63
- PA2056 product record
- PMC10962206 — TP63 truncating mutation causes increased cell apoptosis and premature ovarian insufficiency by enhanced transcriptional activation of CLCA2 (Journal of ovarian research, 2024)
- PMC6548645 — Loss of TP63 Promotes the Metastasis of Head and Neck Squamous Cell Carcinoma by Activating MAPK and STAT3 Signaling (Molecular cancer research : MCR, 2019)
- PMC11014717 — TP63 fusions drive multicomplex enhancer rewiring, lymphomagenesis, and EZH2 dependence (Science translational medicine, 2023)